腹部阻断血流灌注可克服系统预处理后的晚期FIGO IIIc和IV期卵巢癌的耐药性。

Abdominal stop flow infusion breaks drug resistance in systemically pretreated progressive FIGO IIIc and IV ovarian cancer.

作者信息

Aigner K R, Gailhofer S, Brammer C

机构信息

Dept. of Surgical Oncology, Asklepios Paulinen Klinik, Wiesbaden, Germany.

出版信息

Gan To Kagaku Ryoho. 1998 Jan;25(1):111-4.

PMID:9464336

Abstract

Fourty-five patients with progressive FIGO IIIc (36/45 pts.) and IV (9/45 pts.) ovarian cancer, who were in progression under prior cisplatin-based chemotherapy, were submitted to aortic infusion and stop flow infusion with the same drugs. 36/45 patients (80%) had four-quadrant and 9/45 patients (20%) had two-quadrant peritoneal carcinosis, 33/45 with severe ascites. Overall clinical response was 93%: 5/45 CR (11%), 21/45 PR (47%), 16/45 MR (35%). Complete resolution of ascites occurred in 9/33 patients (27%), a substantial reduction of ascites of more than 50% in 14/33 patients (43%). Median survival time was 12.5 months, median time to progression 8.6 months. Toxicity was minimal and in most patients performance and quality of life improved shortly after therapy.

摘要

45例FIGO IIIc期（36/45例）和IV期（9/45例）的晚期卵巢癌患者，在先前基于顺铂的化疗过程中出现病情进展，接受了相同药物的主动脉灌注和阻断血流灌注治疗。36/45例患者（80%）有四象限腹膜转移，9/45例患者（20%）有两象限腹膜转移，33/45例有严重腹水。总体临床缓解率为93%：5/45例完全缓解（CR，11%），21/45例部分缓解（PR，47%），16/45例疾病稳定（MR，35%）。9/33例患者（27%）腹水完全消退，14/33例患者（43%）腹水显著减少超过50%。中位生存时间为12.5个月，中位疾病进展时间为8.6个月。毒性极小，大多数患者在治疗后不久身体状况和生活质量得到改善。